Tirzepatide + Acetaminophen
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Overweight
Conditions
Overweight, Obesity, Diabetes Mellitus, Type 2
Trial Timeline
Sep 15, 2020 → Jan 7, 2021
NCT ID
NCT04407234About Tirzepatide + Acetaminophen
Tirzepatide + Acetaminophen is a phase 1 stage product being developed by Eli Lilly for Overweight. The current trial status is completed. This product is registered under clinical trial identifier NCT04407234. Target conditions include Overweight, Obesity, Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04407234 | Phase 1 | Completed |
Competing Products
20 competing products in Overweight